Supplemental Data for A Phase II Study of Talazoparib Tosylate in Advanced Cancer Patients with Somatic and Germline (not Breast or Ovarian Cancer) Alterations of BRCA1/2, Mutations/Deletions/Amplification in Other Homologous Recombination Repair Pathway Genes and PTEN or PTEN Loss